Skip to main content
Erschienen in: International Journal of Clinical Oncology 1/2013

01.02.2013 | Original Article

Locoregional recurrence risk factors in breast cancer patients with positive axillary lymph nodes and the impact of postmastectomy radiotherapy

verfasst von: Tomoya Nagao, Takayuki Kinoshita, Nobuko Tamura, Takashi Hojo, Madoka Morota, Yoshikazu Kagami

Erschienen in: International Journal of Clinical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Locoregional recurrence (LRR) after mastectomy reduces the patient’s quality of life and survival. There is a consensus that postmastectomy radiotherapy (PMRT) helps establish locoregional control and reduces LRR in patients with ≥4 metastatic nodes. However, in patients with 1–3 metastatic nodes, the incidence of LRR and the role of PMRT have been the subject of substantial controversy. This study assessed the risk factors for LRR and the efficacy of PMRT in Japanese breast cancer patients with metastatic nodes.

Methods

This study analyzed 789 cases of invasive breast carcinoma with metastatic nodes from 1998 to 2008. We divided the study population into 4 groups: 1–3 positive nodes with/without chemotherapy and ≥4 positive nodes with/without chemotherapy. Risk factors for LRR were identified and the relationship between LRR and PMRT was analyzed.

Results

During the median follow-up of 59.6 months, 61 (7.7%) patients experienced LRR. In patients who received chemotherapy, independent LRR risk factors were high nuclear grade, severe lymphatic invasion, vascular invasion, and progesterone receptor-negative status in patients with 1–3 positive nodes, and severe lymphatic invasion and estrogen receptor-negative status in patients with ≥4 nodes. Although patients treated with PMRT had good outcomes, there was no significant difference, and PMRT did not significantly improve the outcome of the patients with all risk factors.

Conclusions

With systemic therapy and adequate dissection, PMRT by itself was of limited value in establishing locoregional control. The indication for PMRT in patients with 1–3 positive nodes remains controversial.
Literatur
1.
Zurück zum Zitat Overgaad M, Hansen PS, Overgaard J et al (1997) Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 337:949–955CrossRef Overgaad M, Hansen PS, Overgaard J et al (1997) Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 337:949–955CrossRef
2.
Zurück zum Zitat Ragaz J, Jackson SM, Le N et al (1997) Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337:956–962PubMedCrossRef Ragaz J, Jackson SM, Le N et al (1997) Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337:956–962PubMedCrossRef
3.
Zurück zum Zitat Olson JE, Neuberg D, Pandya KJ et al (1997) The role of radiotherapy in the management of operative locally advanced breast cancer: results of a randomized trial by the Eastern Cooperative Oncology Group. Cancer 79:1138–1149PubMedCrossRef Olson JE, Neuberg D, Pandya KJ et al (1997) The role of radiotherapy in the management of operative locally advanced breast cancer: results of a randomized trial by the Eastern Cooperative Oncology Group. Cancer 79:1138–1149PubMedCrossRef
4.
Zurück zum Zitat Pierce LJ (2006) The use of radiotherapy after mastectomy: a review of the literature. J Clin Oncol 23:1706–1717CrossRef Pierce LJ (2006) The use of radiotherapy after mastectomy: a review of the literature. J Clin Oncol 23:1706–1717CrossRef
5.
Zurück zum Zitat Katz A, Strom EA, Buchholz TA et al (2001) The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. Int J Radiat Oncol Biol Phys 50:733–742 Katz A, Strom EA, Buchholz TA et al (2001) The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. Int J Radiat Oncol Biol Phys 50:733–742
6.
Zurück zum Zitat Overgaard M, Nielsen HM, Overgaard J (2007) Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 82:247–253PubMedCrossRef Overgaard M, Nielsen HM, Overgaard J (2007) Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 82:247–253PubMedCrossRef
7.
Zurück zum Zitat Truong PT, Olivotto IA, Whelan TJ et al (2004) Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy. CMAJ 170:1263–1273PubMedCrossRef Truong PT, Olivotto IA, Whelan TJ et al (2004) Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy. CMAJ 170:1263–1273PubMedCrossRef
8.
Zurück zum Zitat Marks LB, Zeng J, Prosnitz LR (2008) One to three versus four or more positive nodes and postmastectomy radiotherapy: time to end the debate. J Clin Oncol 28:2075–2077CrossRef Marks LB, Zeng J, Prosnitz LR (2008) One to three versus four or more positive nodes and postmastectomy radiotherapy: time to end the debate. J Clin Oncol 28:2075–2077CrossRef
9.
Zurück zum Zitat Goldhirsch A, Glick JH, Gelber RD et al (1998) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 90:1601–1608PubMedCrossRef Goldhirsch A, Glick JH, Gelber RD et al (1998) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 90:1601–1608PubMedCrossRef
10.
Zurück zum Zitat Goldhirsch A, Glick JH, Gelber RD et al (2001) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Clin Oncol 19:3817–3827PubMed Goldhirsch A, Glick JH, Gelber RD et al (2001) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Clin Oncol 19:3817–3827PubMed
11.
Zurück zum Zitat Goldhirsch A, Wood WC, Gelber RD et al (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357–3365 Goldhirsch A, Wood WC, Gelber RD et al (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357–3365
12.
Zurück zum Zitat Goldhirsch A, Glick JH, Gelber RD et al (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569–1583PubMedCrossRef Goldhirsch A, Glick JH, Gelber RD et al (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569–1583PubMedCrossRef
13.
Zurück zum Zitat Goldhirsch A, Wood WC, Gelber RD et al (2007) Progress and promise: highlights of international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133–1144PubMedCrossRef Goldhirsch A, Wood WC, Gelber RD et al (2007) Progress and promise: highlights of international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133–1144PubMedCrossRef
14.
Zurück zum Zitat The World Health Organization (1983) The World Health Organization histological typing of breast tumors second edition. Am J Clin Pathol 78:806–816 The World Health Organization (1983) The World Health Organization histological typing of breast tumors second edition. Am J Clin Pathol 78:806–816
15.
Zurück zum Zitat Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histopathological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRef Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histopathological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRef
16.
Zurück zum Zitat The Japanese Breast Cancer Society (2008) General rules for clinical and pathological recording of breast cancer, 16th edn. Kanehara, Tokyo (in Japanese) The Japanese Breast Cancer Society (2008) General rules for clinical and pathological recording of breast cancer, 16th edn. Kanehara, Tokyo (in Japanese)
17.
Zurück zum Zitat Tsuda H, Akiyama F, Kurosumi M et al (1998) Establishment of histological criteria for high-risk node-negative breast carcinoma for a multi-institutional randomized clinical trial of adjuvant therapy. Jpn J Clin Oncol 28:486–491PubMedCrossRef Tsuda H, Akiyama F, Kurosumi M et al (1998) Establishment of histological criteria for high-risk node-negative breast carcinoma for a multi-institutional randomized clinical trial of adjuvant therapy. Jpn J Clin Oncol 28:486–491PubMedCrossRef
18.
Zurück zum Zitat Katz A, Strom EA, Buchholz TA et al (2000) Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implication for postoperative irradiation. J Clin Oncol 18:2817–2827PubMed Katz A, Strom EA, Buchholz TA et al (2000) Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implication for postoperative irradiation. J Clin Oncol 18:2817–2827PubMed
19.
Zurück zum Zitat Wallgren A, Bonetti RD, Gelber RD et al (2003) Risk factors for locoregional recurrence among breast cancer patients: results from international breast cancer study group trials I through VII. J Clin Oncol 21:1205–1213PubMedCrossRef Wallgren A, Bonetti RD, Gelber RD et al (2003) Risk factors for locoregional recurrence among breast cancer patients: results from international breast cancer study group trials I through VII. J Clin Oncol 21:1205–1213PubMedCrossRef
20.
Zurück zum Zitat Nielsen HM, Overgaard M, Grau C et al (2006) Loco-regional recurrence after mastectomy in high-risk breast cancer-risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials. Radiother Oncol 79:147–155PubMedCrossRef Nielsen HM, Overgaard M, Grau C et al (2006) Loco-regional recurrence after mastectomy in high-risk breast cancer-risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials. Radiother Oncol 79:147–155PubMedCrossRef
21.
Zurück zum Zitat Yildirum E (2009) Locoregional recurrence in breast carcinoma patients. Eur J Surg Oncol 35:258–265CrossRef Yildirum E (2009) Locoregional recurrence in breast carcinoma patients. Eur J Surg Oncol 35:258–265CrossRef
22.
Zurück zum Zitat Taghian A, Jeong JH, Mamounas E et al (2004) Patterns of locoregional failure in patients with operative breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol 22:4247–4254PubMedCrossRef Taghian A, Jeong JH, Mamounas E et al (2004) Patterns of locoregional failure in patients with operative breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol 22:4247–4254PubMedCrossRef
23.
Zurück zum Zitat Kyndi M, Sørensen FB, Knudsen H et al (2009) Response to postmastectomy radiotherapy in high-risk breast cancer: the Danish breast cancer cooperate group. J Clin Oncol 26:1419–1426CrossRef Kyndi M, Sørensen FB, Knudsen H et al (2009) Response to postmastectomy radiotherapy in high-risk breast cancer: the Danish breast cancer cooperate group. J Clin Oncol 26:1419–1426CrossRef
Metadaten
Titel
Locoregional recurrence risk factors in breast cancer patients with positive axillary lymph nodes and the impact of postmastectomy radiotherapy
verfasst von
Tomoya Nagao
Takayuki Kinoshita
Nobuko Tamura
Takashi Hojo
Madoka Morota
Yoshikazu Kagami
Publikationsdatum
01.02.2013
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 1/2013
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-011-0343-y

Weitere Artikel der Ausgabe 1/2013

International Journal of Clinical Oncology 1/2013 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.